At the 2026 International Cancer Neuroscience Symposium in Houston (USA) the prestigious scientific forum organized by MD Anderson Cancer Center and Advanced Portfolio, Professor Francesco Bifari, co-founder and Director of Therapy Development at Hemera, was invited to present in the “Inflamed Scientists – Elevator Pitch” session dedicated to Innate Immunity.
The invitation recognized his research on the regenerative potential of reprogrammed macrophages, the scientific foundation underlying Hemera’s REMaST® cell therapy platform for the treatment of traumatic spinal cord injury (SCI).
The inclusion in a symposium primarily focused on oncology highlights the growing international interest in innovative macrophage-based cell therapy approaches with cross-therapeutic applications from regenerative medicine to oncology. The recognition of this research in such a high-profile multidisciplinary setting reinforces the scientific robustness on which Hemera is building its industrial and strategic development toward a Phase 1 first-in-human clinical trial.
Participation in a global forum of this level expands the international visibility of the REMaST technology and opens new avenues for dialogue with the global scientific and biotech ecosystem, consolidating Hemera’s positioning as an innovative player in the field of Advanced Therapy Medicinal Products (ATMP).
Learn more about REMaST therapy here